BioCentury
ARTICLE | Company News

Mountain View Pharmaceuticals Inc., Schering deal

January 31, 2005 8:00 AM UTC

SCH received exclusive worldwide development and marketing rights to Mountain View's pegylated interferon-beta-1b to treat multiple sclerosis (MS). Terms were not disclosed. ...